文献速递淋巴瘤造血干细胞移植与细胞治疗

CAR-HEMATOTOX评分可识别接受brexucabtagene autoleucel治疗的复发或难治性套细胞淋巴瘤患者中血液学毒性、感染并发症及不良治疗结局的高危人群

The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL.
PubMed 文献 · Am J Hematol · 2023-08-16

这项多中心观察性研究纳入103例接受brexu-cel治疗的复发或难治性套细胞淋巴瘤患者,描述细胞减少和感染情况,并分析基线CAR-HEMATOTOX评分与毒性事件、非复发死亡及生存的关联。HThigh组中性粒细胞减少持续时间更长、严重感染率更高、1年非复发死亡率更高,90天完全缓解率、无进展生存和总生存均更差。

要点

  • HThigh组中性粒细胞减少中位14天 vs HTlow组6天,p < .001。
  • HThigh组严重感染率30% vs HTlow组5%,p = .001。
  • HThigh组90天完全缓解率68% vs HTlow组93%,p = .002。

核心结论

  • brexu-cel治疗后感染和血液学毒性常见,并导致非复发死亡。
  • 基线CAR-HEMATOTOX评分可识别治疗结局不良风险增加的患者。

研究设计与样本

  • 多中心观察性研究,纳入103例接受brexu-cel治疗的复发或难治性套细胞淋巴瘤患者。
  • 在淋巴细胞清除时,56例为HTlow(评分0-1),47例为HThigh(评分≥2)。

主要发现

  • HThigh组中性粒细胞减少持续时间中位14天 vs HTlow组6天,p < .001。
  • HThigh组严重感染率30% vs HTlow组5%,p = .001。
  • 1年非复发死亡率为10.4%,主要归因于感染,HThigh组17% vs HTlow组4.6%,p = .04。
  • HThigh组90天完全缓解率68% vs HTlow组93%,p = .002。
  • HThigh组无进展生存中位9个月 vs HTlow组未达到,p < .0001;总生存中位26个月 vs HTlow组未达到,p < .0001。

关键数值与推荐

  • 多变量分析显示,高HT评分与严重血液学毒性、感染及不良无进展生存/总生存独立相关。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CD19-directed CAR T-cell therapy with brexucabtagene autoleucel (brexu-cel) has substantially improved treatment outcomes for patients with relapsed/refractory mantle cell lymphoma (r/r MCL). Prolonged cytopenias and infections represent common and clinically relevant side effects. In this multicenter observational study, we describe cytopenias and infections in 103 r/r MCL patients receiving brexu-cel. Furthermore, we report associations between the baseline CAR-HEMATOTOX (HT) score and toxicity events, non-relapse mortality (NRM), and progression-free/overall survival (PFS/OS). At lymphodepletion, 56 patients were HTlow (score 0-1) while 47 patients were HThigh (score ≥2). The HThigh cohort exhibited prolonged neutropenia (median 14 vs. 6 days, p < .001) and an increased rate of severe infections (30% vs. 5%, p = .001). Overall, 1-year NRM was 10.4%, primarily attributed to infections, and differed by baseline HT score (high vs. low: 17% vs. 4.6%, p = .04). HThigh patients experienced inferior 90-day complete response rate (68% vs. 93%, p = .002), PFS (median 9 months vs. not-reached, p < .0001), and OS (median 26 months vs. not-reached, p < .0001). Multivariable analyses showed that high HT scores were independently associated with severe hematotoxicity, infections, and poor PFS/OS. In conclusion, infections and hematotoxicity are common after brexu-cel and contribute to NRM. The baseline HT score identified patients at increased risk of poor treatment outcomes.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Rejeski K, Wang Y, Albanyan O, et al. The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL. Am J Hematol. 2023. PMID: 37584447. doi:10.1002/ajh.27056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。